Achieving high non-viral transfection performance for cell therapy processing

Recently, there has been renewed interest in non-viral gene modification as an alternative to lentiviral vectors. Non-viral electroporation utilizing CRISPR-Cas9 is continuing to show improved performance and safety benefits in the area of cell-based immunotherapy. Furthermore, because electroporation is easy and rapid, it is able to transfect a large number of cells in a short time once optimum electroporation conditions are determined. During this webinar, we will discuss the Gibco™ CTS™ Xenon™ Electroporation System, which has been developed to deliver reliably high transfection performance in volumes of 1–25 mL in a closed system with improved cell viability and recovery.

Please enter your email to access content Read now